title: Actualities in Ovarian Cancer in the Perspective of 2015 (ASCO and ECCO).
abstract: Ovarian cancer represents the 4-th reason of cancer related death in women, the majority of patients being diagnosed in advanced stages of the disease, (III-IV). The loco-regional advanced ovarian cancer should be considered a chronic disease, with multiple evolutionary relapses and where the adjuvant treatment is mandatory.The treatment of the disease is multidisciplinary and the oncologist is the centerpiece.
authors.forename: Dana Lucia
authors.initials: DL
authors.lastname: Stanculeanu
authors.forename: Daniela
authors.initials: D
authors.lastname: Mosoiu
authors.forename: Alecu
authors.initials: A
authors.lastname: Mihnea
authors.forename: Laurentiu
authors.initials: L
authors.lastname: Simion
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D014408:Biomarkers, Tumor / Q000097:blood*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D055088:Early Detection of Cancer; D019317:Evidence-Based Medicine; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D009154:Mutation; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics / Q000401:mortality; D010793:Phthalazines / Q000008:administration & dosage; D010879:Piperazines / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D010793:Phthalazines; D010879:Piperazines; D000068258:Bevacizumab; C531550:olaparib